Table 3.
Incidence of solicited local symptoms (during the 4-day) and fever (during the 15-day and 43-day) postvaccination period (total vaccinated cohort)
| MMRV/MMRV group |
MMR/MMRV group |
MMR/MMR+V group |
||||
|---|---|---|---|---|---|---|
| Dose 1 N*=174; Dose 2 N*=155 |
Dose 1 N*=172; Dose 2 N*=159 |
Dose 1 N*=84; Dose 2 N*=79 |
||||
| Per cent† | (95% CI) | Per cent† | (95% CI) | Per cent† | (95% CI) | |
| Pain | ||||||
| Postdose 1 | 11.5 | (7.2 to 17.2) | 7.0 | (3.7 to 11.9) | 10.7 | (5.0 to 19.4) |
| Postdose 2 | 5.8 | (2.7 to 10.7) | 6.3 | (3.1 to 11.3) | 3.8 | (0.8 to 10.7) |
| Redness | ||||||
| Postdose 1 | 8.6 | (4.9 to 13.8) | 4.7 | (2.0 to 9.0) | 3.6 | (0.7 to 10.1) |
| Postdose 2 | 6.5 | (3.1 to 11.5) | 3.8 | (1.4 to 8.0) | 0.0 | (0.0 to 4.6) |
| Swelling | ||||||
| Postdose 1 | 4.6 | (2.0 to 8.9) | 2.9 | (1.0 to 6.7) | 3.6 | (0.7 to 10.1) |
| Postdose 2 | 5.8 | (2.7 to 10.7) | 3.8 | (1.4 to 8.0) | 0.0 | (0.0 to 4.6) |
| Fever (15 days postdose 1) | ||||||
| Any | 32.2 | (25.3 to 39.7) | 28.5 | (21.9 to 35.9) | 21.7 | (13.4 to 32.1) |
| Grade 3 (>39.5°C) | 3.4 | (1.3 to 7.4) | 1.7 | (0.4 to 5.0) | 1.2 | (0.0 to 6.5) |
| Related | 28.2 | (21.6 to 35.5) | 24.4 | (18.2 to 31.5) | 16.9 | (9.5 to 26.7) |
| Medical advice | 6.3 | (3.2 to 11.0) | 7.6 | (4.1 to 12.6) | 2.4 | (0.3 to 8.4) |
| Fever (15 days postdose 2) | ||||||
| Any | 17.4 | (11.8 to 24.3) | 13.2 | (8.4 to 19.5) | 15.2 | (8.1 to 25.0) |
| Grade 3 (>39.5°C) | 1.3 | (0.2 to 4.6) | 1.3 | (0.2 to 4.5) | 0.0 | (0.0 to 4.6) |
| Related | 13.5 | (8.6 to 20.0) | 11.9 | (7.4 to 18.0) | 12.7 | (6.2 to 22.0) |
| Medical advice | 3.9 | (1.4 to 8.2) | 1.3 | (0.2 to 4.5) | 1.3 | (0.0 to 6.9) |
| Fever (43 days postdose 1) | ||||||
| Any | 43.7 | (36.2 to 51.4) | 40.7 | (33.3 to 48.4) | 32.5 | (22.6 to 43.7) |
| Grade 3 (>39.5°C) | 6.3 | (3.2 to 11.0) | 2.9 | (1.0 to 6.7) | 1.2 | (0.0 to 6.5) |
| Related | 30.5 | (23.7 to 37.9) | 27.9 | (21.3 to 35.2) | 18.1 | (10.5 to 28.0) |
| Medical advice | 13.8 | (9.0 to 19.8) | 16.9 | (11.6 to 23.3) | 4.8 | (1.3 to 11.9) |
| Fever (43 days postdose 2) | ||||||
| Any | 26.5 | (19.7 to 34.1) | 23.3 | (16.9 to 30.6) | 27.8 | (18.3 to 39.1) |
| Grade 3 (>39.5°C) | 1.3 | (0.2 to 4.6) | 3.8 | (1.4 to 8.0) | 2.5 | (0.3 to 8.8) |
| Related | 14.2 | (9.1 to 20.7) | 13.2 | (8.4 to 19.5) | 12.7 | (6.2 to 22.0) |
| Medical advice | 4.5 | (1.8 to 9.1) | 5.6 | (2.6 to 10.5) | 7.6 | (2.8 to 15.8) |
*Number of children with at least one documented dose.
†Percentage of children reporting the symptom at least once.
MMR, measles-mumps-rubella vaccine; MMRV, measles-mumps-rubella-varicella vaccine; MMR+V, MMR+varicella vaccine.